Analysts with Canaccord and Piper Sandler downgraded Globus Medical, anticipating challenges with the deal, expected to close midyear.
“We see a bunch of challenges to the deal, namely differing cultures, sales force and customer dislocation, and doubling down (essentially) in a slower growth category of orthopedics, which is the spine market,” Piper Sandler analyst Matt O’Brien wrote in a stock note.
Analyst Kyle Rose echoed Mr. O’Brien and defended Canaccold’s Globus Medical downgrade to “hold.”
“This is a true downgrade … almost entirely on the view that shares are unlikely to work in the near term given investor concerns about M&A related disruption,” Mr. Rose wrote in a stock note. “This deal brings incremental uncertainty around integration and operational challenges, and we believe shares are appropriately priced and likely to remain range-bound until the dust settles on the M&A.”
Amid buzz of Globus Medical’s acquisition, spine devicemaker Alphatec saw a stock boost of 8.5 percent, Seeking Alpha reported. The company could capture more shares as Globus Medical and NuVasive merge.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
